Camila - Drug Monograph

Comprehensive information about Camila including mechanism, indications, dosing, and safety information.

Introduction

Camila is a progestin-only oral contraceptive tablet containing 0.35 mg of norethindrone. It belongs to the class of medications known as mini-pills and is used primarily for pregnancy prevention. Unlike combination oral contraceptives, Camila does not contain estrogen, making it suitable for certain patient populations who cannot tolerate estrogen-containing products.

Mechanism of Action

Norethindrone, the active ingredient in Camila, acts through multiple mechanisms to prevent pregnancy:

  • Thickening of cervical mucus, creating a barrier to sperm penetration
  • Suppression of the midcycle luteinizing hormone (LH) surge
  • Alteration of the endometrial lining, making it less receptive to implantation
  • In some cases, inhibition of ovulation (though this occurs less consistently than with combination oral contraceptives)

Indications

  • Prevention of pregnancy
  • May be considered for women who:

- Cannot tolerate estrogen-containing contraceptives - Are breastfeeding (typically starting at 6 weeks postpartum) - Have contraindications to estrogen therapy - Experience estrogen-related side effects

Dosage and Administration

Standard dosing: One tablet (0.35 mg norethindrone) taken orally at the same time every day, continuously without a hormone-free interval. Special populations:
  • Postpartum: May be initiated immediately postpartum (non-breastfeeding women) or at 6 weeks postpartum (breastfeeding women)
  • Switching from combination OCs: Start Camila the day after the last active combination OC tablet
  • After abortion or miscarriage: May be started immediately
  • Hepatic impairment: Contraindicated in acute liver disease
  • Renal impairment: No dosage adjustment required

Pharmacokinetics

Absorption: Norethindrone is rapidly absorbed following oral administration, with peak serum concentrations occurring within 1-2 hours. Absolute bioavailability is approximately 65%. Distribution: extensively bound to plasma proteins (primarily albumin and sex hormone-binding globulin). Volume of distribution is approximately 4 L/kg. Metabolism: Undergoes extensive hepatic metabolism primarily via reduction followed by sulfate and glucuronide conjugation. The cytochrome P450 system (particularly CYP3A4) is involved in metabolism. Elimination: Plasma elimination half-life is approximately 8 hours. Excretion occurs primarily in urine (approximately 50%) and feces (approximately 40%).

Contraindications

  • Known or suspected pregnancy
  • Current or history of breast cancer
  • Undiagnosed abnormal genital bleeding
  • Acute liver disease or liver tumors
  • Hypersensitivity to any component of Camila

Warnings and Precautions

Ectopic pregnancy: Be alert to the possibility of ectopic pregnancy in women who become pregnant or complain of lower abdominal pain while using progestin-only contraceptives. Ovarian cysts: Functional ovarian cysts may occur and may require monitoring. Carbohydrate metabolism: Carefully monitor diabetic patients as glucose tolerance may be altered. Liver function: Discontinue if jaundice develops. Vision changes: Discontinue if unexplained partial or complete loss of vision, onset of proptosis, or diplopia occurs. Bleeding patterns: Irregular bleeding is common and may include spotting, prolonged bleeding, or amenorrhea.

Drug Interactions

Enzyme inducers: Drugs that induce hepatic enzymes may decrease norethindrone concentrations:
  • Rifampin
  • Barbiturates
  • Carbamazepine
  • Phenytoin
  • St. John's Wort
  • Modafinil
Antibiotics: Some antibiotics may potentially reduce efficacy, though evidence is limited. HIV medications: Protease inhibitors and non-nucleoside reverse transcriptase inhibitors may affect norethindrone levels.

Adverse Effects

Very common (>10%):
  • Menstrual irregularities
  • Headache
  • Nausea
  • Breast tenderness
  • Dizziness
Common (1-10%):
  • Weight changes
  • Acne
  • Decreased libido
  • Mood changes
  • Fatigue
Serious (rare but important):
  • Ectopic pregnancy
  • Thrombotic events (risk lower than with combination OCs)
  • Hepatic adenomas
  • Breast cancer

Monitoring Parameters

  • Pregnancy status (if suspected)
  • Blood pressure (baseline and periodically)
  • Bleeding patterns
  • Breast examination
  • Liver function (if symptoms suggest dysfunction)
  • Visual changes (if reported)
  • Weight changes
  • Mood changes

Patient Education

  • Take at the same time every day (within a 3-hour window for maximum effectiveness)
  • If a dose is missed by more than 3 hours, use backup contraception for 48 hours
  • Irregular bleeding patterns are common, especially during the first few months
  • Does not protect against sexually transmitted infections
  • Contact healthcare provider if severe abdominal pain, chest pain, headaches, visual changes, or jaundice occur
  • May decrease milk production in breastfeeding women
  • Effectiveness may be reduced with concomitant use of certain medications
  • Return to fertility is rapid after discontinuation

References

1. FDA Prescribing Information for Camila (norethindrone) tablets 2. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(4):1-66. 3. Truitt ST, Fraser AB, Grimes DA, et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev. 2003;(2):CD003988. 4. Kaunitz AM. Progestin-only oral contraception: a comprehensive review. Contraception. 1994;50(6 Suppl 1):S1-S195. 5. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: WHO; 2015. 6. Hatcher RA, Nelson AL, Trussell J, et al. Contraceptive Technology. 21st ed. New York: Ayer Company Publishers; 2018.

Medical Disclaimer

The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

The content on MedQuizzify is designed to support, not replace, the relationship that exists between a patient and their healthcare provider. If you have a medical emergency, please call your doctor or emergency services immediately.

How to Cite This Article

admin. Camila - Drug Monograph. MedQuizzify [Internet]. 2025 Sep 07 [cited 2025 Sep 08]. Available from: http://medquizzify.pharmacologymentor.com/blog/drug-monograph-camila

Enjoyed this post?

Subscribe to our newsletter and get more educational insights, quiz tips, and learning strategies delivered weekly to your inbox.